文献速递抗栓抗凝管理药物不良反应与药物警戒

四因子凝血酶原复合物给药时机与剂量对华法林相关颅内出血结局的影响

Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
PubMed 文献 · Pharmacotherapy · 2022-04-28

单中心回顾性分析94例华法林相关颅内出血患者,评估4F-PCC给药时间及剂量与临床结局的关系。INR充分逆转者主要终点发生率低于未充分逆转者(28.1% vs 58.6%;p=0.0059)。体重剂量组抗凝逆转失败率低于固定剂量组(24.2% vs 65.0%;p<0.001)。

要点

  • INR充分逆转(≤1.3)与较低的主要终点发生率相关。
  • 体重剂量较固定剂量抗凝逆转失败率更低。
  • GCS<15患者中不同给药时机或剂量策略的临床结局无差异。

核心结论

  • GCS<15患者中,4F-PCC给药时机或剂量策略未观察到临床结局差异。
  • 体重剂量给药时重复INR≤1.3的比例更高,提示需研究固定剂量可能不适用的人群。

研究设计与样本

  • 单中心回顾性分析,纳入94例年龄≥18岁、因华法林导致INR>1的颅内出血患者,均接受4F-PCC和静脉维生素K逆转抗凝。

主要发现

  • 91-120分钟组主要终点发生率71.4%,>120分钟组30.6%,两组差异显著(p=0.005),但校正GCS差异后不显著。
  • INR充分逆转组主要终点发生率28.1%,未充分逆转组58.6%(p=0.0059)。
  • 体重剂量组抗凝逆转失败率24.2%,固定剂量组65.0%(p<0.001)。

关键数值与推荐

  • 主要终点为血肿扩大(影像学评估)或神经损伤死亡的复合终点。
  • INR充分逆转定义为重复INR≤1.3。
  • 给药时间窗分组:0-30、31-60、61-90、91-120、>120分钟。

临床怎么用

  • 华法林相关颅内出血使用4F-PCC时,体重剂量可能提高INR逆转成功率。
  • 应关注INR逆转是否充分(≤1.3),因其与临床结局相关。
  • GCS<15患者中给药时机选择可能不影响结局,但需结合个体情况。

局限性

  • 单中心回顾性设计可能引入选择偏倚。
  • 样本量较小(94例),部分亚组事件数少。
  • GCS差异可能影响给药时间与结局的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The objective of this study was to evaluate clinical outcomes associated with time to administration and dose of four-factor prothrombin complex concentrate (4F-PCC) in patients with ICH on warfarin. DESIGN: This was a single-center retrospective analysis of patients with ICH on warfarin who received 4F-PCC. SETTING: The site of the study was a large, Level I trauma, academic medical center with a dedicated neurologic intensive care unit and an emergency department (ED) that has approximately 72,000 visits annually. PATIENTS: Patients were included if they were ≥18 years of age, diagnosed with ICH, had an INR >1 due to warfarin use, and received both 4F-PCC and IV vitamin K for anticoagulation reversal. Exclusion criteria included patients who were less than 18 years of age, were not currently taking warfarin, had a bleeding site other than ICH, were pregnant or incarcerated, had an inadequate medical record, had a left ventricular assist device, had known liver disease with Child-Pugh Class C, received anticoagulation with heparin therapy within 24 h of anticoagulation reversal, or did not receive vitamin K within 24 h of hospital admission. INTERVENTION: Our primary outcome was a composite of hematoma expansion or death due to neurologic injury. Treatment groups were defined as receipt of 4F-PCC within 0-30, 31-60, 61-90, 91-120 min, or greater than 120 min. Hematoma expansion was defined as any increase in hematoma size as assessed by a radiologist via standard 6-h CT. Death due to neurologic injury was defined as death prior to a repeat CT being performed or documentation of a neurologic cause of death. Adequate INR reversal (INR ≤1.3 on repeat INR) vs. inadequate INR reversal and weight-based vs. fixed-dose 4F-PCC were also assessed. MEASUREMENTS AND MAIN RESULTS: A total of 94 patients met the inclusion criteria. Forty-one patients (43.6%) met the composite endpoint, including 60% of the 31-60 min group, 47.6% of the 61-90 min group, 71.4% of the 91-120 min group, and 30.6% of the >120-min group. A significant difference in primary outcome occurred between the 91-120 min and >120-min groups (71.4% vs. 30.6%; p= 0.005), but this difference was not observed when accounting for disparities in Glasgow Coma Scale (GCS). Patients with adequate INR reversal were less likely to meet the primary endpoint than those with inadequate INR reversal (28.1% vs. 58.6%; p= 0.0059). There was less failure of anticoagulation reversal with weight-based dosing compared with fixed dosing (24.2% vs. 65.0%; p< 0.001). CONCLUSIONS: No difference in clinical outcomes among 4F-PCC dosing strategies or time windows to administration was observed in patients with GCS <15. Rates of repeat INR ≤1.3 were higher with weight-based dosing, suggesting investigation of populations in which fixed dosing may be inappropriate is warranted.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Cicci CD, Weiss A, Dang C, et al. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage. Pharmacotherapy. 2022. PMID: 35384000. doi:10.1002/phar.2680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。